Holen Sie sich die Stockscreener-App
27.39
0.94%
-0.26
Handel nachbörslich:
27.38
-0.01
-0.04%
Schlusskurs vom Vortag:
$27.65
Offen:
$27.85
24-Stunden-Volumen:
99,047
Relative Volume:
0.67
Marktkapitalisierung:
$379.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.48M
KGV:
-18.71
EPS:
-1.4641
Netto-Cashflow:
$-8.59M
1W Leistung:
+4.10%
1M Leistung:
+13.14%
6M Leistung:
+228.02%
1J Leistung:
+179.20%
1-Tages-Spanne:
$27.03
$28.94
1-Wochen-Bereich:
$26.00
$28.94
52-Wochen-Spanne:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Firmenname
Greenwich Lifesciences Inc
Sektor
Branche
Telefon
203-434-3290
Adresse
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
27.39 | 383.08M | 0 | -19.48M | -8.59M | -1.4641 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-20 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-09-01 | Eingeleitet | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Aktie (GLSI) Neueste Nachrichten
(GLSI) Volatility Zones as Tactical Triggers - Stock Traders Daily
Greenwich LifeSciences receives Nasdaq noncompliance notice By Investing.com - Investing.com Nigeria
Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-Q filing - MSN
Greenwich LifeSciences: Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - Moomoo
Greenwich LifeSciences receives Nasdaq noncompliance notice - Investing.com
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - Weekly Voice
Nasdaq flags breast cancer drug developer over late SEC filing - Stock Titan
GLSI Stock Chart | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Greenwich Lifesciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Price-Driven Insight from (GLSI) for Rule-Based Strategy - Stock Traders Daily
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Greenwich LifeSciences (NASDAQ:GLSI) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Greenwich LifeSciences (GLSI) shares fall 3% despite tiny EPS beat; investors demand clinical progress updates. - newser.com
(GLSI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Greenwich LifeSciences delays annual report filing - Investing.com UK
Greenwich LifeSciences delays annual report filing By Investing.com - Investing.com Australia
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing - The Manila Times
Europe trial enrollment jump leaves Greenwich finalizing 10-K figures - Stock Titan
GLSI Stock Price, Quote & Chart | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Why did Greenwich LifeSciences stock soar pre-market today? - MSN
Should investors enter Greenwich LifeSciences (GLSI) stock today | Greenwich LifeSciences posts tiny EPS beat, no revenue reportedCrowd Stock Picks - Newser
Why is GLSI stock rising today? - MSN
Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-K filing - MSN
Greenwich LifeSciences (NASDAQ:GLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Greenwich LifeSciences (GLSI) and Actinogen Medical (OtherATGGF) - The Globe and Mail
HC Wainwright Has Bearish Estimate for GLSI FY2026 Earnings - MarketBeat
ASCO 2026 to feature Greenwich LifeSciences research poster - Traders Union
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 - ChartMill
GLSI (Greenwich LifeSciences Inc.) reports narrow Q3 2025 EPS beat, shares climb 2.36 percent on positive investor sentiment.Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - ChartMill
H.C. Wainwright Maintains Greenwich LifeSciences(GLSI.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Nasdaq flags Greenwich LifeSciences over delayed 2025 annual report - Stock Titan
(GLSI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Why Did GLSI Stock Rise Pre-Market Today? - Stocktwits
Why did GLSI stock rise pre-market today? - MSN
Greenwich LifeSciences shares rise on breast cancer vaccine trial data By Investing.com - Investing.com Canada
Greenwich LifeSciences unveils preliminary FLAMINGO-01 open label data at AACR Meeting - Traders Union
Breast cancer immunotherapy shows 4x immune response in Phase III data - Stock Titan
Is Greenwich LifeSciences (GLSI) stock still attractive (Bullish Sentiment) 2026-04-18Stock Idea Sharing Hub - Xã Thanh Hà
Greenwich LifeSciences (GLSI) Stock Rule Based Trade (Investors Pile In) 2026-04-16Shared Buy Zones - Xã Châu Thành
Greenwich LifeSciences (GLSI) Stock Rights Issue (At Lows) 2026-04-15Viral Trades - Xã Thanh Hà
Greenwich Lifesciences Provides Clinical Trial and Pipeline Update - National Today
Greenwich LifeSciences reports Q1 cash balance of $10.5 million By Investing.com - Investing.com Australia
Strategic financing update revealed by Greenwich LifeSciences - Traders Union
Finanzdaten der Greenwich Lifesciences Inc-Aktie (GLSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Greenwich Lifesciences Inc-Aktie (GLSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):